Mr. Fredric Warren Feist Sr., M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 425 5th Ave Nw, Attalla, AL 35954 Phone: 256-492-7800 Fax: 256-494-5536 |
News Archive
Second Sight Medical Products Inc. today announces that the French Ministry of Health has officially approved financial support for the Argus II Retinal Prosthesis System. Through the Forfait Innovation scheme, the French Government will pay for the first wave of groundbreaking treatment for 36 patients with severe to total sight loss due to retinitis pigmentosa (RP) in France.
Fewer patients undergoing aortic valve replacement (AVR) are being re-hospitalized in the year following surgery, indicating the surgery is safer and the recovery has become easier, according to an article in the February 2015 issue of The Annals of Thoracic Surgery.
Researchers from Chalmers University of Technology, Sweden, have created a new, rubber-like material with a unique set of properties, which could act as a replacement for human tissue in medical procedures.
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.
Colonies of the multicellular green alga Volvox carteri exposed to temperatures of 111 degrees Fahrenheit (42.5 degrees Celsius) had twice the amount of free radicals, oxidants that can damage biological structures, as unheated colonies. High levels of oxidants within their cells activated the algae's sex-inducer gene, the researchers report.
› Verified 2 days ago